Pfizer company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A widely circulated market note argues Pfizer’s shares could re-rate toward $50 if multiple expansion returns, even as revenue declines tied to Comirnaty and Paxlovid continue to weigh on sentiment.
THE APEX TIMES
THE APEX TIMES
At the American Diabetes Association’s 2026 Scientific Sessions, investors weighed new clinical updates from Eli Lilly, Pfizer, and Roche as the obesity drug market prepares for more entrants beyond the current leaders.
THE APEX TIMES
The deal gives Pfizer early access to Chai-3 and a custom version of the platform built with Pfizer’s proprietary data, as the two companies move from AI research toward deployment inside drug discovery workflows.
THE APEX TIMES
The pharmaceutical company says it will gain early access to Chai-3 and deploy the platform inside its drug-discovery workflow, with Chai citing a doubling of antibody design success versus its prior model.
THE APEX TIMES
A recent rebound in Pfizer’s stock has revived debate about valuation, as the company balances dividend support and investment in oncology and obesity programs against a still-transitioning revenue base.
THE APEX TIMES
New findings presented at the American Diabetes Association meeting add to Pfizer’s case that berobenatide (PF’3944) can sustain weight loss after switching from weekly injections to monthly maintenance, with gastrointestinal tolerability described as favorable.
THE APEX TIMES
At the American Diabetes Association meeting, Pfizer reported additional evidence that berobenatide (PF’3944) could deliver continued weight loss after transitioning from weekly dosing to once-monthly maintenance, as the company steps up its late-stage program planning.
THE APEX TIMES
At a time when Pfizer shares imply a dividend yield near 6.7%, the company’s latest earnings materials stress preserving the payout through a difficult patent-loss transition, while building confidence in cash flow later in the decade.
THE APEX TIMES
A new licensing and collaboration deal with Innovent Biologics is designed to build a pipeline that could help replace revenue as key franchises near loss of patent protection.
